TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. The US Food and Drug Administration has cleared Tyra's Investigational New Drug application to ...

Nina S. Kjellson, a director at Tyra Biosciences , Inc. (NASDAQ:TYRA), recently made several transactions involving the sale of common stock in the company. According to a recent SEC filing ...

Hey, I'm Ryan Pearson. I'm an entertainment video manager for the Associated Press in Los Angeles. And um I am back at my house in Al Sadina for the first time since the day of the fires.

Tyra Banks is among the thousands of people in Los Angeles who have been impacted by the still-active wildfires that have swept through the area, but she's thankful that most of her cherished ...